2024年第四季度Apyx Medical GAAP每股收益$(0.12)优于预期$(0.15),销售额$1422万超过预期$1339万

财报速递
03-13
Apyx Medical(NASDAQ:APYX)公布的季度亏损为每股$(0.12),优于分析师一致预期的$(0.15),超出预期20%。相比去年同期每股$(0.28)的亏损,实现了57.14%的增长。公司报告的季度销售额为$1422万,超过分析师一致预期的$1339万,超出预期6.21%。相比去年同期的$1466万,销售额下降了3.01%。

以上内容来自Benzinga Earnings专栏,原文如下:

Apyx Medical (NASDAQ:APYX) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.15) by 20 percent. This is a 57.14 percent increase over losses of $(0.28) per share from the same period last year. The company reported quarterly sales of $14.22 million which beat the analyst consensus estimate of $13.39 million by 6.21 percent. This is a 3.01 percent decrease over sales of $14.66 million the same period last year.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10